Single-use Bioreactors Market (2023-2030)
The Single-use Bioreactors Market is projected to reach $10.3 billion by 2030, at a CAGR of 15.8% from 2023 to 2030.
- Published
- May 2023
- Pages
- 251
- Format
- PDF + Excel
- Report ID
- MRHC - 104303
- Base year
- 2022
- 2030 · FORECAST
- $10.30B
- 2030
- $10.30B
- CAGR 2023–2030
- 15.8%
2022 baseline · 2023–2030 forecast at 15.8% CAGR · hover a bar for the value
Key highlights
Based on Product, the Media Bags Segment is Projected to Register the Highest CAGR
Based on type, the Wave-induced Bioreactors Segment is Projected to Register the Highest CAGR
In 2023, the Mammalian Cells Segment is Expected to Account for the Largest Share
In 2023, the Commercial Bio-Production Segment is Expected to Account for the Largest Share
In 2023, the Pharmaceutical & Biopharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2022 |
| Estimated Year | 2023 |
| Forecast Period | 2023–2030 |
| Market Size (2030) | USD 10.30 billion |
| CAGR (2023–2030) | 15.8% |
| Format | PDF, Excel & Cloud Portal · 251 pages |
| Segments Covered | By Product: Single-use Bioreactor Systems Upto 10L, 11L-500L, 501-1000L, Above 1001L, 2D, 3D, Linear · By Type: Stirred-tank Bioreactors, Wave-induced Bioreactors, Other Types · By Cell Type: Mammalian cells, Bacterial Cells, Yeast Cells, Other Cell Types · By Application: Commercial Bioproduction Monoclonal Antibody Production, Vaccine Production, Therapeutic Protein Production, Cell & Gene Therapy · By End User: Pharmaceutical and Biopharmaceutical Companies, Academic & Research Institutes · By Cell: Mammalian, Bacterial, Yeast |
| Countries Covered | Europe (RoE), Asia-Pacific (RoAPAC) |
| Key Companies | Merck KGaA, Danaher Corporation, Sartorius AG, Thermo Fisher Scientific Inc., Eppendorf AG, Cellexus International Ltd., CESCO Bioengineering Co., Ltd., PBS Biotech, Inc., Distek, Inc., Infors AG |
Report overview
Segments covered: product, type, cell type, application, end user, cell. Regions: Europe, Asia-Pacific.
Single-use bioreactors, also called disposable bioreactors, are made of disposable bags instead of a culture vessel. These bioreactors eliminate the need for expensive and bulky clean-in-place (CIP) or steam-in-place (SIP) systems and offer flexibility and a low risk of contamination, contributing to their adoption by pharma & biotech companies. These companies are focusing on organic & inorganic strategies like expanding manufacturing capacity or acquisitions to increase their bioproduction, increasing the adoption of biopharma equipment, including bioreactors.
For instance, in December 2022, Thermo Fisher Scientific Inc. (U.S.) expanded its presence in Hangzhou, China, to support customers' manufacturing needs, enabling them to serve more patients worldwide. This site offers integrated clinical and commercial drug substance and drug product capabilities, including process development, cell line development, biologics drug substance manufacturing and sterile fill-finish. This includes the use of packaging and labeling capabilities. Advanced technologies in the facility include Thermo Fisher 2,000-liter HyPerforma Single-Use Bioreactors and associated Single-Use equipment and, in the future, bioreactor capacity up to 5,000 liters through Thermo Scientific DynaDrive technology.
In March 2021, Pall Corporation (U.S.), a subsidiary of Danaher Corporation (U.S.), acquired Pall-Austar Lifesciences Limited (Hong Kong) (a joint Venture between Pall and Austar Group). This acquisition is intended to expand the single-use technology manufacturing capabilities of the company in China for products supporting the scale-up of COVID-19 vaccines.
The rapid adoption of disposable technology in the pharmaceutical and biotechnology industry, growing demand for biopharmaceuticals, and capacity expansion of biopharmaceutical plants are some of the major factors driving the growth of the single-use bioreactors market.
Report infographic
Market dynamics
1 factors across 1 forceThe Rising Adoption of Personalized Medicines is an Opportunity for the Players in this Market
Personalized medicine is an emerging practice that uses an individual's genetic profile to guide disease prevention, diagnosis, and treatment decisions. These medicines are now considered the mainstream clinical approach, thereby changing disease identification, classification, and treatment method.
According to a report published by the Personalized Medicine Coalition, personalized medicines are increasing rapidly. The share of personalized medicine increased steadily in the total drugs approved in the U.S. by FDA from 28% in 2015 to 35% in 2021. In 2021, the FDA’s Center for Drug Evaluation and Research (CDER) approved 48 new molecular entities (NMEs) (drugs, agents, or therapeutic biologics). Out of these 48 drugs, 17 were classified as personalized medicines. Globally, the number of personalized medicines was 132 in 2016, which increased to 286 in 2020. The increasing number of FDA approvals and the availability of new personalized medicines are expected to create demand for their upstream processing equipment, such as bioreactors.
Table of contents
13 chapters · 97 sections · 251 pages · click to expandSegmental analysis
| Segment | Largest share (2023) | Fastest growth (2023–2030) |
|---|---|---|
| By Product | — | — |
| By Type | — | — |
| By Cell Type | Mammalian Cells | — |
| By Application | Commercial Bio-Production | — |
| Other segments | Pharmaceutical & Biopharmaceutical Companies | — |
By Product
- The Media Bags Segment is Projected to Register the Highest CAGR
- The growth of this segment is driven by its benefits, such as high flexibility, low levels of extractable and leachable, and product stability during storage compared to culture vessels.
By Type
- The Wave-induced Bioreactors Segment is Projected to Register the Highest CAGR
- In contrast to conventional stirred tank bioreactors, wave-induced bioreactor systems do not rely on oxygen bubbles for culture aeration or agitators for mixing.
- Instead, these bioreactors' large surface-to-volume ratio and rocking motion generate surface aeration to meet the oxygen demands of mammalian cell cultures, often exceeding those delivered by stirred tanks.
- Rocking-motion bioreactor systems have also been shown to improve fluid turnover and minimize shear forces compared to stirred tanks.
- Such flow conditions reportedly produce better cell suspension and reduce the risk of cell damage, enabling rocking-motion bioreactors to reach higher maximum cell densities than traditional spinner flasks.
- All these advantages of wave-induced bioreactors contribute to the growth of this segment.
By Cell Type
- The mammalian cells segment is expected to account for the largest share of the market.
- Mammalian cells are mostly used for mAbs production and can produce large amounts of mAbs with a consistent quality and adapt well to culture in large-scale suspension bioreactors.
- These cells can perform the required protein folding, assembly and post-translational modifications such as glycosylation and provide greater commercial success for protein & genomic research, thus driving the adoption of single-use bioreactors.
By Application
- The commercial bio-production segment is expected to account for the largest share of the market.
- The large market share of this segment is attributed to the growing support from regulatory agencies & initiatives by biopharma companies.
- For instance, in October 2021, the U.S. Food and Drug Administration, the National Institutes of Health (NIH), 10 pharmaceutical companies, and five non-profit organizations partnered to accelerate the development of gene therapies for the 30 million Americans suffering from rare diseases.
- In January 2021, Cognate BioServices, Inc. (U.S.), a cell and gene therapy CDMO, announced plans to expand its cell and gene therapy manufacturing facility, warehouse capabilities, and laboratory space at its U.S. and European sites.
Other segments
- The Pharmaceutical & Biopharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market
- The large market share of this segment is attributed to the rise in R&D activities, high adoption of bioreactors in pharmaceutical laboratories, and concerns over flexibility, sterility, cost efficiency, and enhanced productivity.
Geographic analysis
Europe
Largest shareThe growth of this market is driven by the increasing sales of drugs, support from government and regulatory authorities to promote the use of biopharmaceuticals for various health indications, and various companies expanding their manufacturing capacities as well as their operations. Europe: Largest Regional Market
Competitive landscape
- Merck KGaA
- Danaher Corporation
- Sartorius AG
- Thermo Fisher Scientific Inc.
- Eppendorf AG
- Cellexus International Ltd.
- CESCO Bioengineering Co., Ltd.
- PBS Biotech, Inc.
- Distek, Inc.
- Infors AG
Frequently asked questions
This study offers a detailed assessment of the single-use bioreactors market, including the market size & forecast for various segmentations, including product, type, cell type, application, and end user. The single-use bioreactors market studied in this report also involves the value analysis of various segments and sub-segments of single-use bioreactors at regional and country levels.
Cite this report
Meticulous Research. (2023). Single-use Bioreactors Market - Global Opportunity Analysis and Industry Forecast (2023-2030) (Report No. MRHC - 104303). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/single-use-bioreactors-market-5005